BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 18767027)

  • 1. Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases.
    Robbins CM; Hernandez W; Ahaghotu C; Bennett J; Hoke G; Mason T; Pettaway CA; Vijayakumar S; Weinrich S; Furbert-Harris P; Dunston G; Powell IJ; Carpten JD; Kittles RA
    Prostate; 2008 Dec; 68(16):1790-7. PubMed ID: 18767027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men.
    Rennert H; Zeigler-Johnson CM; Addya K; Finley MJ; Walker AH; Spangler E; Leonard DG; Wein A; Malkowicz SB; Rebbeck TR
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):949-57. PubMed ID: 15824169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men.
    Beuten J; Gelfond JA; Franke JL; Shook S; Johnson-Pais TL; Thompson IM; Leach RJ
    Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):588-99. PubMed ID: 20086112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma.
    Noonan-Wheeler FC; Wu W; Roehl KA; Klim A; Haugen J; Suarez BK; Kibel AS
    Prostate; 2006 Jan; 66(1):49-56. PubMed ID: 16114055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer.
    Xu J; Zheng SL; Carpten JD; Nupponen NN; Robbins CM; Mestre J; Moses TY; Faith DA; Kelly BD; Isaacs SD; Wiley KE; Ewing CM; Bujnovszky P; Chang B; Bailey-Wilson J; Bleecker ER; Walsh PC; Trent JM; Meyers DA; Isaacs WB
    Am J Hum Genet; 2001 Apr; 68(4):901-11. PubMed ID: 11254448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational analysis of susceptibility genes RNASEL/HPC1, ELAC2/HPC2, and MSR1 in sporadic prostate cancer.
    Nupponen NN; Wallén MJ; Ponciano D; Robbins CM; Tammela TL; Vessella RL; Carpten JD; Visakorpi T
    Genes Chromosomes Cancer; 2004 Feb; 39(2):119-25. PubMed ID: 14695991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between RNASEL, MSR1, and ELAC2 single nucleotide polymorphisms and gene expression in prostate cancer risk.
    Alvarez-Cubero MJ; Pascual-Geler M; Martinez-Gonzalez LJ; Expósito Ruiz M; Saiz M; Cozar JM; Lorente JA
    Urol Oncol; 2016 Oct; 34(10):431.e1-8. PubMed ID: 27318894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variation in RNASEL and risk for prostate cancer in a population-based case-control study.
    Fesinmeyer MD; Kwon EM; Fu R; Ostrander EA; Stanford JL
    Prostate; 2011 Oct; 71(14):1538-47. PubMed ID: 21360564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans.
    Shook SJ; Beuten J; Torkko KC; Johnson-Pais TL; Troyer DA; Thompson IM; Leach RJ
    Clin Cancer Res; 2007 Oct; 13(19):5959-64. PubMed ID: 17908993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population.
    Agalliu I; Leanza SM; Smith L; Trent JM; Carpten JD; Bailey-Wilson JE; Burk RD
    Prostate; 2010 Nov; 70(15):1716-27. PubMed ID: 20564318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of heterozygosity of the putative prostate cancer susceptibility gene HPC2/ELAC2 is uncommon in sporadic and familial prostate cancer.
    Wu YQ; Chen H; Rubin MA; Wojno KJ; Cooney KA
    Cancer Res; 2001 Dec; 61(24):8651-3. PubMed ID: 11751379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men.
    Takahashi H; Lu W; Watanabe M; Katoh T; Furusato M; Tsukino H; Nakao H; Sudo A; Suzuki H; Akakura K; Ikemoto I; Asano K; Ito T; Wakui S; Muto T; Hano H
    Int J Cancer; 2003 Nov; 107(2):224-8. PubMed ID: 12949798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene.
    Maier C; Haeusler J; Herkommer K; Vesovic Z; Hoegel J; Vogel W; Paiss T
    Br J Cancer; 2005 Mar; 92(6):1159-64. PubMed ID: 15714208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNASEL and RNASEL-inhibitor variation and prostate cancer risk in Afro-Caribbeans.
    Shea PR; Ishwad CS; Bunker CH; Patrick AL; Kuller LH; Ferrell RE
    Prostate; 2008 Mar; 68(4):354-9. PubMed ID: 18189233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer.
    Wiklund F; Jonsson BA; Brookes AJ; Strömqvist L; Adolfsson J; Emanuelsson M; Adami HO; Augustsson-Bälter K; Grönberg H
    Clin Cancer Res; 2004 Nov; 10(21):7150-6. PubMed ID: 15534086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer.
    Rökman A; Ikonen T; Mononen N; Autio V; Matikainen MP; Koivisto PA; Tammela TL; Kallioniemi OP; Schleutker J
    Cancer Res; 2001 Aug; 61(16):6038-41. PubMed ID: 11507049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ELAC2 polymorphisms and prostate cancer risk: a meta-analysis based on 18 case-control studies.
    Xu B; Tong N; Li JM; Zhang ZD; Wu HF
    Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):270-7. PubMed ID: 20231859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of HPC2/ELAC2 polymorphisms with risk of prostate cancer in a population-based study.
    Stanford JL; Sabacan LP; Noonan EA; Iwasaki L; Shu J; Feng Z; Ostrander EA
    Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):876-81. PubMed ID: 14504198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer.
    Yokomizo A; Koga H; Kinukawa N; Tsukamoto T; Hirao Y; Akaza H; Mori M; Naito S
    Prostate; 2004 Nov; 61(3):248-52. PubMed ID: 15368467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPC2/ELAC2 gene variants associated with incident prostate cancer.
    Adler D; Kanji N; Trpkov K; Fick G; Hughes RM
    J Hum Genet; 2003; 48(12):634-638. PubMed ID: 14625808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.